A Phase II Study of Sequential Carfilzomib, Clarithromycin (Biaxin), Lenalidomide (Revlimid), and Dexamethasone (Decadron) [Car-BiRD] Therapy for Subjects With Newly Diagnosed Multiple Myeloma

Trial Profile

A Phase II Study of Sequential Carfilzomib, Clarithromycin (Biaxin), Lenalidomide (Revlimid), and Dexamethasone (Decadron) [Car-BiRD] Therapy for Subjects With Newly Diagnosed Multiple Myeloma

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 12 Dec 2017

At a glance

  • Drugs Carfilzomib (Primary) ; Clarithromycin; Dexamethasone; Lenalidomide
  • Indications Multiple myeloma
  • Focus Therapeutic Use
  • Acronyms CarBiRD
  • Most Recent Events

    • 12 Dec 2017 Results of a retrospective analysis assessing the safety and efficacy of Carfilzomib in patients from this study (NDMM) with renal involvement, presented at the 59th Annual Meeting and Exposition of the American Society of Hematology.
    • 06 Dec 2016 Results presented at the 58th Annual Meeting and Exposition of the American Society of Hematology.
    • 22 May 2013 Results will be presented at the 18th Congress of the European Hematology Association (EHA).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top